ofatumumab + bendamustine

DRUG3 trials

Sponsors

Nevada Cancer Institute, Memorial Sloan Kettering Cancer Center

Conditions

Chronic Lymphocytic Leukemia (CLL)Mantle Cell Lymphoma

Phase 2

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

TerminatedNCT01125787

Nevada Cancer InstituteChronic Lymphocytic Leukemia (CLL)

Start: 2010-05-31End: 2011-04-30Updated: 2011-07-20

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

WithdrawnNCT01131247

Nevada Cancer InstituteChronic Lymphocytic Leukemia (CLL)

Target: 37Updated: 2011-07-20

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

CompletedNCT01437709

Memorial Sloan Kettering Cancer CenterMantle Cell Lymphoma

Start: 2011-09-30End: 2023-09-12Updated: 2025-02-28